A brief review paper of the efficacy and safety of atorvastatin in early clinical trials

Atherosclerosis

Volumn 131, Issue 1, 1997, Pages 17-23

  Bakker Arkema, Rebecca G ^a   Best, James ^b   Fayyad, Rana ^a   Heinonen, Therese M ^a   Marais, A David ^c   Nawrocki, James W ^a   Black, Donald M ^a  

^a PFIZER INC   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Atorvastatin; Combined hyperlipidemia; Dyslipidemia; Hypercholesterolemia; Hypertriglyceridemia; Reducta se inhibitor

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 1; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0030960751     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(97)06066-8     Document Type: Article

References (31)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023.
2. European Atherosclerosis Society. Prevention of coronary heart disease: scientific background and new clinical practice guidelines. Nutr Metab Cardiovasc Dis 1992;2:113-156.
3. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
4. Shepherd J, Stuart CM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;20:1301-1307.
5. Brown BG, Albers JJ, Hollger L et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-1298.
6. Buchwald H et al. Effect of partial ileal bypass on mortality and morbidity from coronary artery disease in patients with hypercholesterolemia - report of the Program on surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990;323:946.
7. Watts GF, Lewis B, Brunt JNH et al. Effects on coronary artery disease of lipid lowering diet, or diet plus cholestyramine, in the St. Thomas' atherosclerosis regression study (STARS). Lancet 1992;339:563-569.
8. Blankenhorn DH, Nessin SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary bypass grafts. JAMA 1989;257:3233-3240.
9. Brensike JF et al. Effects of therapy with cholestyramine on progression of coronary atherosclerosis: results of the NHLBI type II coronary intervention study. Circulation 1984;69:313-324.
10. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results: 1. Reduction in incidence of coronary artery disease. JAMA 1984;251:351-364.
11. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler 1991;11:2-14.
12. Hulley SB, Rosenman RH, Bawol RD, Brand RJ. Epidemiology as a guide to clinical decisions: the association between triglyceride and coronary artery disease. N Engl J Med 1980;302:1383-1389.
13. Mahley RW, Rall SC, Jr. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. 6th ed. New York: McGraw-Hill, 1989;1195-1213.
14. Grundy SM, Vega GL. Two different views of the relationship of hypertriglyceridemia to coronary artery disease. Arch Intern Med 1992;152:28-34.
15. Genest JJ, Jr, Martin-Munley SS, McNamara JR et al. Prevalence of familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992;85:2025-2033.
16. Nawrocki JW, Weiss SR, Davidson MH et al. Reduction of LDL-cholesterol by 25-60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler 1995;15:678-682.
17. Seiler KU, Wolffenbuttel BHR, Mahla D et al. Comparison of atorvastatin, a new HMG-CoA reductase inhibitor, with pravastatin and simvastatin. Atherosclerosis. 1994;109(special issue):314. Abstract 217.
18. Bakker-Arkema R, Davidson MH, Goldstein R et al. The efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996;275:128-133.
19. Naoumova RP, Marais AD, Mountney J et al. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolemia. Atherosclerosis 1996;119:203-213.
20. Best JD, Nicholson GC, O'Neal DN et al. Atorvastatin and simvastatin reduce elevated cholesterol in non-insulin dependent diabetes. Diab Nutr Metab. 1996;9:74-80.
21. Heinonen TM, Schrott H, McKenney JM et al. Atorvastatin, a new HMG-CoA reductase inhibitor as mono-therapy and combined with colestipol. J Cardiol Pharmacol Therap 1996;2:117-122.
22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the ultracentrifuge. Clin Chem 1972;18:449-502.
23. Manual of laboratory operations lipid research clinics program. In: Hainline A, Karon J, Lippel K, eds. Lipid and Lipoprotein Analysis, 2nd edn. Bethesda, MD: National Heart, Lung, and Blood Institute, National Institutes of Health 1982;5.
24. Ma PTS, Gil G, Sudhf TC, Bilheimer DW, Goldstein JL, Brown MS. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci USA 1986;83:8370-8374.
25. Kasim SE, LeBoeuf RC, Khilnani S, Tallapaka L, Dayananda D, Jen KL. Mechanisms of triglyceride-lowering effect of HMG-CoA reductase inhibitor in a hypertriglyceridemic model, the Zucker obese rat. J Lipid Res 1992;33:1-7.
26. Shaw MK, Newton RS, Sliskovic DR, Roth BD, Ferguson E, Krause BR. Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase. Biochem Biophys Res Commun 1990;170:726-734.
27. Gibson DM, Bron NJ, Richens A, Hounslow NJ, Sedman AJ, Whitfield LR. Effect of age and gender on pharmacokinetics of atorvastatin in humans. J Clin Pharmacol 1996;36:242-246.
28. Stender S, Zilversmit DB. Transfer of plasma lipoprotein components and of plasma proteins into aortas of cholesterol-fed rabbits: molecular size as a determinant of plasma lipoprotein influx. Arterioscler 1981;1:28-49.
29. Vega GL, Grundy SM. Does measurement of apolipoprotein B have a place in cholesterol management? Arterioscler 1990;10:668-671.
30. Krause BR, Newton RS. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models. Atherosclerosis 1995;117:237-244.
31. Frick MH, Elo O, Kauko H et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317:1237-1245.